Soleno Therapeutics, Inc.
SLNO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.96 | 0.07 | -0.09 |
| FCF Yield | -3.84% | -3.76% | -25.01% | -17.00% |
| EV / EBITDA | -10.20 | -13.35 | -3.11 | -4.71 |
| Quality | ||||
| ROIC | -60.01% | -24.42% | -126.15% | -113.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.39 | 0.64 | 0.86 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -177.92% | -19.94% | 25.18% | -10.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 4.57 | 0.65 | 0.69 |
| Interest Coverage | -812.43 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |